Latanoprost ophthalmic - ClinicalTrials.gov

Open Label Study to Evaluate the Safety, Tolerability and Biodegradation Period of PA5346 Latanoprost Free Acid (FA) Sustained Release (SR) Ocular Implant When Administered to Patients With Open Angle Glaucoma or Ocular Hypertension

Eye drops that are at least 28 days and no more than 49 days prior to the day of implant administration will be discontinued. Participants were also expected to have unmedicated IOP u2265 20 mmHg and u2264 36 mmHg at 12:00 noon and 4:00 p. m. in the same screen visit where the 8:00 AM IOP was IOP u2265 24 mmHg and u2264 36mmHg was obtained on the same screening visit.

Source link: https://clinicaltrials.gov/ct2/show/NCT05333419

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions